Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for aggressive blood cancer: drug combo targets Richter's transformation

NCT ID NCT04679012

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 28 times

Summary

This study tests a new drug combination (polatuzumab vedotin plus chemotherapy) in 20 adults with Richter's transformation, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. Participants receive up to six cycles of treatment and are monitored for safety and response. The goal is to see if this approach can control the disease and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact

    Contact

  • Mount Sinai- Icahn School of Medicine

    RECRUITING

    New York, New York, 10029, United States

    Contact

    Contact

  • Ohio state University

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

    Contact

  • Weill Cornell Medicine

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.